This Is MS Multiple Sclerosis Community: Knowledge & Support
Welcome to the world's leading forum on Multiple Sclerosis research, support, and knowledge. For over 10 years, This is MS has provided an unbiased community dedicated to Multiple Sclerosis patients, caregivers, and affected loved ones.
Dacluzimab results
1 post
• Page 1 of 1
Dacluzimab results
by bromley » Wed Sep 28, 2005 5:55 am
-
bromley - Family Elder
- Posts: 1887
- Joined: Fri Sep 10, 2004 2:00 pm
Advertisement
1 post
• Page 1 of 1
-
- Related topics
- Replies
- Views
- Last post
-
- Dacluzimab trial
by bromley » Fri Nov 04, 2005 8:57 am - 1 Replies
- 2023 Views
- Last post by dignan
Fri Nov 04, 2005 11:45 am
- Dacluzimab trial
-
- Laquinimod results
by bromley » Wed Sep 28, 2005 5:51 am - 0 Replies
- 1221 Views
- Last post by bromley
Wed Sep 28, 2005 5:51 am
- Laquinimod results
-
- Tovaxin results
by bromley » Wed Sep 28, 2005 6:00 am - 4 Replies
- 2056 Views
- Last post by ewizabeth
Wed Dec 06, 2006 1:59 pm
- Tovaxin results
-
- Tauferon results
by bromley » Wed Sep 28, 2005 6:06 am - 0 Replies
- 1541 Views
- Last post by bromley
Wed Sep 28, 2005 6:06 am
- Tauferon results
-
- MN 166 trial results
by bromley » Tue Mar 27, 2007 6:17 am - 4 Replies
- 1371 Views
- Last post by dignan
Wed Mar 28, 2007 7:13 am
- MN 166 trial results
Who is online
Users browsing this forum: No registered users
News
Site map
SitemapIndex
RSS Feed
This site does not offer, or claim to offer, medical, legal, or professional advice.
All treatment decisions should always be made with the full knowledge of your physicians.
This is MS does not create, endorse, or republish any content. All postings are the responsibility of the poster. All logos and trademarks in this site are property of their respective owners. All users must respect our rules for intellectual property rights.
This is MS does not create, endorse, or republish any content. All postings are the responsibility of the poster. All logos and trademarks in this site are property of their respective owners. All users must respect our rules for intellectual property rights.
